Novo Nordisk grabs global rights to Hengrui Pharma’s oral GLP-1 GIP drug in $2.6 billion deal
Novo Nordisk has signed a licensing deal worth up to $2.6 billion for Hengrui Pharma’s once-weekly oral GLP-1 GIP agonist HRS-1596. The move shakes up the metabolic disease market.